Promising new agents in the treatment of non-small cell lung cancer

Cancer Chemotherapy and Pharmacology

Volumn 37, Issue 5, 1996, Pages 385-393

  Edelman, Martin J ^a   Gandara, David R ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b NONE

Author keywords

CPT 11; Docetaxel; Gemcitabine; jPaclitaxel; Lung cancer; Topotecan; Vinorelbine

Indexed keywords

DOCETAXEL; EDATREXATE; GEMCITABINE; IRINOTECAN; NAVELBINE; NEW DRUG; PACLITAXEL; TOPOTECAN;

CANCER CHEMOTHERAPY; CARDIOTOXICITY; CLINICAL TRIAL; DIARRHEA; DRUG MECHANISM; HUMAN; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MUCOSA INFLAMMATION; NEUROPATHY; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; REVIEW;

EID: 0030020182     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050402     Document Type: Review

References (89)

1. Abbruzzese JL, Grunewald R, Weeks EA, Gravel D, et al (1991) A phase I clinical, plasma and cellular pharmacology study of gemcitabine. J Clin Oncol 9 : 491
2. Abigerges D, Armand J, Chabot GG, Da Costa L, Fadel E, Cote C, Herait P, Gandia D (1994) Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea. J Nat Cancer Inst 86 : 446
3. Abratt R, Bezwoda W, Falkson G, Goedhals L, Hacking D, Rugg T (1994) Efficacy and safety profile of gemcitabine in non-small cell lung cancer. A phase II study. J Clin Oncol 12 : 1535
4. Albain KS, Crowley J, LeBlanc M, Livingston R (1991) Survival determinants in extensive stage non-small cell lung cancer: the Southwest Oncology Group Experience, J Clin Oncol 9 : 1618
5. Anazi H, Frost P, Abbruzzese JL (1992) Synergistic cytotoxicity with combined inhibition of topoisomerases I and II (Abstract 2573). Proc Amer Assoc Cancer Res 33 : 431
6. Anderson H, Lund B, Bach F, et al (1994) Single agent activity of weekly gemcitabine in advance non-small cell lung cancer: a phase II study. J Clin Oncol 12:(9):1821
7. Balbiani L, Coppola F, Blajman C, et al (1993) Navelbine (nvb) vs NVB plus cisplatin (p) in non-small cell lung cancer (NSCLC) (Abstract 1185). Proc Am Soc Clin Oncol 12 : 352
8. Bertelli P, Mantica C, Farina G, et al (1994) Treatment of non-small cell lung cancer with vinorelbine (Abstract 1218). Proc Am Soc Clin Oncol 13 : 362
9. Binet S, Fellous A, Lataste H, et al (1989) In situ analysis of the action of navelbine on various types of microtubules using immunofluorescence. Semin Oncol 16 [Suppl 4] : 5-8
10. Bishop JF, Taxoid in lung cancer (1994) Lung Cancer 11 [Suppl 2] : 250-1
11. Burris HA, Rothenburg ML, Kuhn JG, et al (1992) Clinical trials with the topoisomerase I inhibitors. Semin Oncol 19 : 663
12. Burris H, Irvin R, Kuhn J, et al (1992) A phase I clinical trial of docetaxel as a 6 hour infusion repeated every 21 days in patients with refractory solid tumors (Abstract 369). Proc Am Soc Clin Oncol 11 : 137
13. Burris H, Echardt J, Fields S, et al (1993) Phase II trials of docetaxel in patients with non-small cell lung cancer (Abstract 1116). Proc Am Soc Clin Oncol 12 : 335
14. Cabrai F, Wible L, Brenner S, et al (1983) Taxol-requiring mutant of chinese hamster ovary cells with impaired mitotic spindle activity. J Cell Biol 97 : 30-39.
15. Cerny T, Kaplan S, Pavlioli N, et al (1994) Taxotere (docetaxel) is an active drug in non-small cell lung cancer: a phase II trial of the EORTC Early Clinical Trials Group (ECTG). Br J CA 70 : 384
16. Chang A, Kim K, Glick J, et al (1993) Phase II study of paclitaxel in patients with stage IV non-small cell lung cancer (NSCLC): The Eastern Cooperative Oncology Group (ECOG) results. J Natl Cancer Inst 85 : 389
17. Cormier Y, Shepherd F, Burkes R, et al (1994) Phase I study of gemcitabine (gem) and cisplatin (cp) for advanced non-small cell lung cancer (NSCLC) (Abstract 1140). Proc Am Soc Clin Oncol 13 : 342
18. Cros S, Wright M, Roussakis C, et al (1989) Experimental antitumor activity of navelbine (5′-nor-anhydrovinblastine, vinorelbine). Semin Oncol 16:(Suppl 4) 15-20
19. Depierre A, Lemarie E, Dabouis G, et al (1988) Phase II study of navelbine (nvb) in non-small cell lung cancer (Abstract 778). Proc Am Soc Clin Oncol 7 : 201
20. Depierre A, Lebeau B, Chastang CI, et al (1993) Result of a phase III randomized study of vinorelbine (v) versus vinorelbine-cisplatin (vp) in non-small cell lung cancer (NSCLC) (Abstract 1138). Proc Am Soc Clin Oncol 12 : 340
21. Diamandidis DT, Lee JS, Shin DM, et al (1994) Phase I study of taxol and edatrexate (edam) chemotherapy in solid tumors (Abstract 453). Proc Am Soc Clin Oncol 13 : 165
22. Dillman RO, Seagren SL, Propert KJ, et al (1990) A randomized trial of induction chemotherapy plus high-dose radiation alone in stage III non-small cell lung cancer. N Engl J Med 323 : 940
23. Drinkard L, Hoffman P, Bitran J, et al (1994) A phase I-II trial of navelbine (n) and ifosfamide (i) with granulocyte colony stimulating factor (G-CSF) support in advanced non-small cell lung cancer (NSCLC) (Abstract 1186). Proc Am Soc Clin Oncol 13 : 354
24. Dunlop DJ, Cameron C, Dabouis G, et al (1994) Phase I dose-escalation study of cisplatin in combination with gemcitabine in non-small cell lung cancer (Abstract 1139). Proc Am Soc Clin Oncol 13 : 342
25. Ettinger DS, Finkelstein DM, Sarma R, et al (1993) Phase II study of taxol in patients (pts) with extensive-stage small cell lung cancer (SCLC): An Eastern Cooperative Oncology Group Study (Abstract 1094). Proc Am Soc Clin Oncol 12 : 329
26. Fennelly DM, Rigas JR, Chou D, et al (1994) Phase I trial of edatrexate plus paclitaxel using an administration of schedule with demonstrated in vitro synergy (Abstract 1232). Proc Am Soc Clin Oncol 13 : 365
27. Forastiere, AA, Rowinsky E, Chaudry V, et al (1992) Phase I trial of paclitaxel and cisplatin + G-CSF in solid tumors (Abstract 289). Proc Am Soc Clin Oncol 11 : 117
28. Fossella FV, Lippman S, Pang A, et al (1993) Phase I/II study of gemcitabine (g) by 30 minute weekly intravenous (iv) infusion × 3 wks every 4 wks for non-small cell lung cancer (NSCLC) (Abstract 1082). Proc Am Soc Clin Oncol 12 : 326
29. Fossella FV, Lee JS, Murphy WK, et al (1994) Phase II study of docetaxel for recurrent or metastatic non-small cell lung cancer. J Clin Oncol 12 : 1238
30. Fossella FV, Lee JS, Shin DM, et al (1995) Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small cell lung cancer. J Clin Oncol 13:(3):645-651
31. Francis PA, Rigas JR, Kris MG, et al (1994) Phase II trial of docetaxel in patients with stage III and IV non-small cell lung cancer. J Clin Oncol 12 : 1232
32. Fukuoka M, Niitani H, Suzuki A, et al (1992) A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small cell lung cancer. J Clin Oncol 10 : 16
33. Galindo E, Kavanagh J, Fossella F, et al (1994) Docetaxel (Taxotere) toxicities: analysis of a single institution experience of 168 patients (623 courses) (Abstract 452). Proc Am Soc Clin Oncol 13 : 164
34. Gandara DR, Perez EA, Edelman MS et al (1995) Phase I trial of (edatrexate) plus carboplatin in advanced solid tumors: amelioration of dose limiting mucosites by ice-chip cryotherapy (Abstract 1513). Proc Am Soc Clin Oncol 14 : 468
35. Grever MR, Schepartz SA, Chabner BA (1992) The National Cancer Institute: cancer drug discovery and development program. Semin Oncol 19 : 622
36. Horwitz SB, Cohen D, Rao S, et al (1993) Taxol: mechanisms of action and resistance. J Natl Cancer Inst 15 : 55-61
37. Ihde DC (1991) Chemotherapy combined with chest irradiation for locally advanced non-small cell lung cancer. Ann Intern Med 115 : 737
38. Israel VK, Zaretsky S, Natale RB (1994) Phase I/II trial of combination carboplatin and taxol in advanced non-small cell lung cancer (NSCLC) (Abstract 1175). Proc Am Soc Clin Oncol 13 : 351
39. Kaye SB (1994) Gemcitabine: current status of phase I and II trials. J Clin Oncol 12 : 1527
40. Kim JH, Kim SH, Kolozsvary A, et al (1992) Potentiation of radiation response in human carcinoma cells in vitro and murine fibrosarcoma in vivo by topotecan, an inhibitor of DNA topoisomerase 1. Int J Rad Oncol Biol Phys 22 : 515
41. Klastersky J, Sculier JP (1994) Paclitaxel (p) plus cisplatin (c) in non-small cell lung cancer: a dose finding study (Abstract 1169). Proc Am Soc Clin Oncol 13 : 349
42. Kris MG, Kinahan JJ, Gralla RJ, et al (1988) Phase I trial and clinical pharmacological evaluation of 10-ethyl-10-deaza-aminopterin in adult patients with advanced cancer. Cancer Res 48 : 5573
43. Kris MG, Gralla RJ, Potanovich LM, et al (1991) Long term survival analysis of stage III and IV non-small cell lung cancer patients treated with edatrexate (Abstract 408). Lung Cancer (Suppl) 7 : 111
44. Langer CJ, Curran WJ, Catalano R, et al (1994) Long term survival results for patients with locally advanced non-small cell lung carcinoma (NSCLC) treated with aggressive concurrent chemoradiotherapy (Abstract 1102). Proc Am Soc Clin Oncol 13 : 333
45. Langer CJ, Leighton J, Comis R, et al (1994) Taxol and carboplatin (CBDCA) in combination in stage IV and IIIB non-small cell lung cancer (NSCLC): a phase II trial (Abstract 1122). Proc Am Soc Clin Oncol 13 : 338
46. Le Chevalier T, Brisgand D, Douillard JY, et al (1994) Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol 12(2): 360
47. Lee JS, Libshitz HI, Murphy WK, et al (1990) Phase II study of 10-ethyl-10-deaza-aminopterin (10-EdAM; CGP 30 694) for stage IIIB or IV non-small cell lung cancer. Investigational New Drugs 8 : 299
48. Lee JS, Libshitz HI, Murphy WK, et al (1991) Edatrexate improves the antitumor effects of cyclophosphamide and cisplatin against non-small cell lung cancer. Cancer 68 : 959
49. Lee JS, Libshitz HI, Fossella FV, et al (1992) Improved therapeutic index by leucovorin of edatrexate, cyclophosphamide and cisplatin against non-small cell lung cancer. J Natl Cancer Inst 84 : 1039
50. Lonardi F, Pavanato G, Jirillo A, et al (1994) Vinorelbine (vnb) as single-agent chemotherapy (ct) in advanced non-small cell lung cancer (NSCLC) patients (pts) (Abstract 1123). Proc Am Soc Clin Oncol 13 : 338
51. Lynch TJ, Kalish L, Strauss G, et al (1994) Phase II study of topotecan in metastatic non-small cell lung cancer. J Clin Oncol 12(2): 347
52. Marantz A, Lewi D, Litovska S, et al (1994) Phase II study of vinorelbine (vn) and ifosfamide (ifx) for non-small cell lung cancer (NSCLC) (Abstract 1071). Proc Am Soc Clin Oncol 13 : 325
53. Masuda N, Fukuoka M, Takada M, et al (1992) CPT-11 in combination with cisplatin for advanced non-small cell lung cancer. J Clin Oncol 10 : 1775
54. Masuda N, Fukuoka M, Yusunoki Y, et al (1993) Phase I study of irinotecan (CPT-11) and cisplatin (CDDP) plus G-CSF for advanced non-small cell lung cancer (NSCLC) (Abstract 1086). Proc Am Soc Clin Oncol 12 : 327
55. Masuda N, Fukuoka M, Kudoh S, et al (1994) Phase I and pharmacologic study of irinotecan and etoposide with recombinant human granulocyte colony-stimulating factor support for advanced lung cancer. J Clin Oncol 12 1833:(No. 9)
56. 2 with prednisone premedication in non-small cell lung cancer (NSCLC) (Abstract 1226). Proc Am Soc Clin Oncol 13 : 364
57. Morere JF, Brunei A, Duran A, et al (1994) Ifosfamide (ifx) and vinorelbine (nvb) in advanced non-small cell lung cancer (NSCLC) (Abstract 1149). Proc Am Soc Clin Oncol 13 : 344
58. Mori K, Suga U, Kishiro I, et al (1994) A phase I study of CPT-11 and cisplatin (5-day continuous infusion) for advanced non-small cell lung cancer (Abstract 1234). Proc Am Soc Clin Oncol 13 : 366
59. Murphy WK, Fossella FV, Winn RJ, et al (1993) A phase II study of taxol in patients with non-small cell lung cancer. J Natl Cancer Inst 85 : 384
60. Murphy WK, Winn RJ, Huber M, et al (1994) Phase II study of taxol (I) in patients (pt) with non-small cell lung cancer (NSCLC) who have failed platinum (p) containing chemotherapy (ctx) (Abstract 1224). Proc Am Soc Clin Oncol 13 : 363
61. Nakagawa K, Fukuoka M, Niitani H, et al (1993) Phase II study of irinotecan (CPT-11) and cisplatin in patients with advanced non-small cell lung cancer (NSCLC) (Abstract 1104). Proc Am Soc Clin Oncol 12 : 332
62. Negoro S, Fukuoka M, Niitani H, et al (1991) Phase II study of CPT-11, new camptothecin derivative, in small cell lung cancer (SCLC) (Abstract 822). Proc Am Soc Clin Oncol 10 : 241
63. Paul DM, Johnson DH, Hande KR, et al (1994) Carboplatin (c) and taxol (t): A well tolerated regimen for advanced non-small cell lung cancer (NSCLC) (Abstract 1181). Proc Am Soc Clin Oncol 13 : 352
64. O'Rourke MA, Crawford J, Schiller J, et al. Survival advantage for patients wilh stage IV NSCLC treated with single agent navelbine in a randomized controlled trial (Abstract 1148) (1993) Proc Am Soc Clin Oncol 12: 343
65. Perez EA, Hack FM, Webber LM, Chou TC (1993) Schedule-dependent synergism of edatrexate and cisplatin combination in the A549 lung cancer cell line as assessed by median effect analysis. Cancer Chemother Pharmacol 33 : 245
66. Perez EA, Hack FM, Fletcher TS, Chou TC (1994) Modulation of intrinsic in vitro resistance to carboplatin by edatrexate in the A549 human non-small cell lung cancer cell line. Oncol Res 6 : 151
67. Perez-Soler R, Glisson BS, Kane J, et al (1994) Phase II study of topotecan in patients with non-small cell lung cancer (NSCLC) previously untreated (Abstract 1223). Proc Am Soc Clin Oncol 13 : 363
68. 1-Difluorodeoxycytidine)(g) over 30 minutes in patients (pts) with non-small cell lung cancer (NSCLC)(Abstract 1147). Proc Am Soc Clin Oncol 13 : 344
69. Ringel I, Horwitz SB (1991) Studies with RP56976 (docetaxel): A semisynthetic analogue of taxol. J Natl Cancer Inst 83:288
70. Rowinsky EK, Donehower RC, Jones RJ, et al (1990) Taxol: a novel investigational antineoplastic agent. J Natl Cancer Inst 82 : 1247
71. Rowinsky EK, Onetto N, Canetta RM, Arbuck SG (1992) Taxol: the first of the taxanes, an important new class of anti-tumor agents. Semin Oncol 19 : 646
72. Rowinsky EK, Chaudhry V, Forastiere AA, et al (1993) Phase I and pharmacologic study of taxol and cisplatin with granulocyte colony-stimulating factor: neuromuscular toxicity is dose-limiting. J Clin Oncol 11 : 2010
73. Rowinsky E, Grochow L, Kaufman S, et al (1994) Sequence-dependent effects of topotecan (t) and cisplatin (c) in a phase I and pharmacokinetic (pk) study (Abstract 361). Proc Am Soc Clin Oncol 13 : 142
74. Saltz L, Sirott M, Young C, et al (1993) Phase I clinical and pharmacology study of topotecan given daily for 5 consecutive days to patients with advanced solid tumors, with attempt at dose intensification using recombinant greanulocyte colony-stimulating factor. J Natl Cancer Inst 85 : 1499
75. Santomaggio C, Righi R, Tucci E, et al (1994) Carboplatin (CBDCA) and vinorelbine (v) in the treatment of patients (pts) affected by advanced non-small cell lung cancer (NSCLC) (Abstract 1211). Proc Am Soc Clin Oncol 13 : 360
76. Schaake-Koning C, van den Bogaert W, Dalesio O, et al (1992) Effects of concomitant cisplatin and radiotherapy on inoperable non-small cell lung cancer. N Engl J Med 326 : 524
77. Schiff PB, Fant J, Horwitz SB (1979) Promotion of microtubule assembly in vitro by taxol. Nature 22 : 665
78. Schmid FA, Sirotnak FM, Otter GM, DeGraw JI (1987) Combination chemotherapy with a new folate analog: Activity of 10-ethyl-10-deaza-aminopterin compared to methotrexate with 5-fluorouracil murine tumor models. Cancer Treat Rep 71 : 727
79. Shepherd FA, Gatzemeier U, Gotfried M, et al (1993) An extended phase II study of gemcitabine in non-small cell lung cancer (NSCLC) (Abstract 1096). Proc Am Soc Clin Oncol 12 : 330
80. Shinkai T, Arioka H, Kunikane H, et al (1993) A phase I study of CPT-11 and cisplatin in combination with fixed dose of vindesine in metastatic non-small cell lung cancer (NSCLC) (Abstract 1089). Proc Am Soc Clin Oncol 12 : 328
81. Shum KY, Kris MG, Gralla RJ, et al (1988) Phase II study of 10-ethyl-10-deaza-aminopterin in patients with stage III and IV non-small cell lung cancer. J Clin Oncol 6 : 446
82. Sirotnak FM, DeGraw JI, Moccio DM, Samuels LL, Goutas LJ (1984) New folate analogs of the 10-deaza-aminopterin series. Basis for structural design and biochemical pharmacological properties. Cancer Chemother and Pharmacol 12 : 18
83. Sirotnak FM, DeGraw JI, Schmidt FA, Goutas LJ, Moccio DM (1984) New folate analogs of the 10-deaza-aminopterin series. Further evidence for markedly increased antitumor efficacy compared to methotrexate in ascites and solid murine tumor models. Cancer Chemother and Pharmacol 12 : 26
84. Souhami RL, Rudd RM, Spiro SG, et al (1992) Phase II study of edatrexate in stage III and IV non-small cell lung cancer. Cancer Chemother and Pharmacol 30 : 465
85. Swenerton K, Eisenhauer, Huinink W, et al (1993) Taxol in relapsed ovarian cancer: high vs low dose and short vs long infusion: A European-Canadian study coordinated by the NCI Canada clinical trials group (Abstract 810). Proc Am Soc Clin Oncol 12 : 256
86. Tomiak E, Piccart MJ, Kerger J, et al (1994) Phase I study of docetaxel administered as a 1-hour intravenous infusion on a weekly basis. J Clin Oncol 12 : 1458
87. Vokes EE, Rosenberg RK, Jahanzeb M, et al (1995) Multicenter phase II study of weekly oral vinorelbine for stage IV non-small cell lung cancer. J Clin Oncol 13 : 637-644
88. Watanabe K, Yokoyama A, Furuse K, et al (1994) Phase II trial of docetaxel in previously untreated non-small cell lung cancer (NSCLC) (Abstract 1095). Proc Am Soc Clin Oncol 13 : 331
89. Yokoyama A, Furuse K, Niitani H, et al (1992) Multi-institutional phase II study of navelbine (vinorelbine) in non-small cell lung cancer (Abstract 957). Proc Am Soc Clin Oncol 11 : 287